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ABSTRACT
Apoptosis, a process in which a cell systematically triggers its own death in response to DNA
damage or external stimuli, is widely utilized in the body to maintain a homeostatic quantity of
cells. Malfunctions in this process can result in numerous consequences, particularly tumor
development. For a cell to undergo apoptosis, there are two major pathways, dependent upon the
method of induction: the extrinsic and intrinsic pathways. The goal of this research is to elucidate
the temporal dynamics of apoptosis in Jurkat T-lymphocytes with respect to caspase activity in
the extrinsically-activated pathway, using fluorescence microscopy. Microfluidic devices were
fabricated from polydimethylsiloxane (PDMS) and contained an antibody-coated channel. The
devices were used for cellular capture of the lymphocytes to trap and observe cells in a
controlled, sustainable- environment for a given duration. The antibody coated in the channel,
anti-CD95, induces apoptosis through Fas receptor binding. The result of the antibody binding is
the activation of a caspase enzyme, creating a destructive caspase cascade. General caspase
activation was visualized over a 9-hour period with the fluorogenic caspase probe L-bisaspartic
acid Rhodamine 110 (D2R). Derivatives of the fluorogenic probe containing sequences to
specific caspases were used to monitor the first and last caspases to be activated in the apoptotic
pathway. The derivative (IETD)2R was used to monitor the primary initiator caspase activation
(caspase-8) and the (DEVD)2R for executioner caspase activation (caspase-3). The overall
average caspase activity began 2.4 ± 0.6 hours post-induction and lasted 360 ± 60 minutes,
caspase-8 activity was shown to start 1.8 ± 0.8 hours after induction and remain active for 120 ±
40 minutes, and caspase-3 activity started 5.2 ± 1.0 hours after induction, lasting 130 ± 60
minutes. Timing of caspase activation is an important field of study as it could be helpful in
designing apoptosis-targeted therapies.
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BSL- biosafety level
D2R- fluorogenic caspase probe (aspartic acid)
DED- death effector domains
(DEVD)2R- fluorogenic caspase probe (aspartic acid, glutamic acid, valine, aspartic acid)
DISC- death-inducing signaling complex
DNA- deoxyribonucleic acid
FADD- Fas-associated death domain
FAK- focal adhesion kinase
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(IETD)2R- fluorogenic caspase probe (isoleucine, glutamic acid, threonine, aspartic acid)
IgM- Immunoglobulin M
PAK2- p21- activated kinase
PBS- phosphate buffered saline
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R110- rhodamine 110
RPMI- Roswell Park Memorial Institute
TBS- Tris-buffered saline
TRAIL- tumor necrosis factor-related apoptosis-inducing ligand
TNF- tumor necrosis factor
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1. INTRODUCTION
1.1 Programmed Cell Death: Apoptosis
The survival and function of multi-cellular organisms is highly dependent upon
regulatory processes which act to maintain homeostasis. Such biological processes include gene
regulation, anabolism, catabolism, chemotaxis and homeostatic temperature regulation in larger
eukaryotic mammalian species. Of the regulatory processes, cell quantity homeostatic regulation
is the most vital for eukaryotic life. Mitosis is the cell division regulation process, which
increases the quantity of cells within the body. Cell death occurs through both apoptosis and
necrosis, which are vital for opposing mitosis to maintain cell quantity.
While both cell death processes are necessary for homeostatic regulation, necrosis is
destructive, induced by irreversible damage in the nucleus or cytoplasm of a cell (1). Necrotic
cells become pockets of acidic cell waste which cause damage to the eukaryotic organism if not
properly disposed of by phagocytosis. The more common form of cell death, apoptosis, occurs
20-40 billion times per day in the adult body (2). This highly regulated programmed cell death
maintains proper cell quantities in the organism. Gene regulation is important in apoptosis, as
selective gene mutations may disrupt the apoptotic pathway, producing diseases (3). Misregulation of apoptosis through overstimulation results in an abundance of inappropriate cell
death. Excessive apoptosis has been linked to neurodegeneration and cell loss in conditions such
as stroke, Alzheimer’s and Huntington’s disease (4). In contrast, mis-regulation of apoptosis
resulting in inhibition of apoptosis leads to excess cellular division. This will often result in
tumor development, high-risk cervical cancer, cerebrovascular accidents and lymphoproliferative
disorders (5). As such, apoptosis is widely recognized as the most common cause of cancer
development and tumor formation (6). Because the dysregulation of apoptosis contributes to a
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variety of human disorders, compounds that promote or inhibit specific forms of apoptosis may
be of considerable therapeutic value (7).
The process of apoptosis itself can be subdivided into three categories: initiation,
effectuation and degradation (8). The initiation stage is further subdivided by the method of
initiation (extrinsic and intrinsic activation). External ligand binding to pro-apoptotic receptors
will initiate extrinsic activation. If the death inducing signal is internally generated, such as
through chromatin damage, initiation is intrinsic (9). Initiation of activation varies between cell
type, but either pathway leads to the same effectuation stage. Both induction pathways are well
studied and often utilized in anti-cancer treatments such as chemotherapy, g-irradiation,
immunotherapy or suicide gene therapy where either the cancerous cells are pushed into
undergoing apoptosis extrinsically or intrinsically (10). Either activation process will result in the
activation of caspases, a family of cysteine proteases which act as common death effector
molecules in cell death (11). However, many tumor cells develop resistance to the intrinsically
activated pathway, so extrinsic investigations are important in the development of targeted- drug
therapies to target caspase activity (5).

1.2 Apoptotic Initiation through Extrinsic Activation
The initiation of apoptosis results in the proteolytic cleavage of procaspases, the zymogen
form of the death-inducing enzymes, caspases. Caspases destroy the cell by command, giving
apoptosis the characteristic name of the pathway of “cellular suicide.” The process begins when
a pro-apoptotic ligand, such as an apoptotic-inducing Fas-ligand, binds to a specialized Fas or
tumor necrosis factor (TNF) membrane receptors (12). Activated receptors involve Fasassociated death domain (FADD) adapter proteins. The FADD aggregation stimulates the
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production of death effector domains (DED) intracellular to the receptor site (Figure 1). DEDs
dimerize with DEDs in the folded-inactive domains of procaspase molecules to form a deathinducing signaling complex (DISC). Procaspases are the zymogen forms of the death-inducing
enzymes, caspases (2,13). The complex includes procaspase-8, the first death-enzyme to become
activated in the induction process. Cleavage of c-FLIPL motif in the DIS-complex activates the
molecule, which will homo-oligomerize. Active caspase-8 in then released into the cytosol,
concluding of the initiation stage (14).

Figure 1: Fas- ligand Binding to Fas ligand
Receptor to Initiate Apoptosis Extrinsically The
binding of a Fas-ligand (anti-CD95) to the Fas
receptor (CD-95) on the Jurkat T lymphocyte leads
to FADD aggregation and the production of the
DEDs at the site of the receptor. Intracellular
cleavage results in the activation of caspase-8 from
procaspase-8. Adapted from Kischkel et. al. (13).
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1.3 Effectuation Stage of Apoptosis and Caspases
The cascade of activation of caspases defines the effectuation stage of apoptosis. The
pinnacle involvement of caspases in apoptosis was first discovered in mice studies. Mice lacking
caspase-3 or caspase-9 had an increased quantity of neurons and reduced apoptosis, compared to
mice with active caspase-3 which were rapidly undergoing apoptosis. Caspases thus played an
important role in apoptosis as the death-effector enzymes involved in the effectuation process
(15). Pro-caspases are transcribed from the ced-3 gene, encoding for the aspartate-specific
cysteine protease (16). The proenzyme (30 to 50 kD) tertiary structure contains two domains, a
large domain (30 kD) and a small domain (20 kD), which are connected by aspartate-containing
linking regions. The amine terminal residues of the procaspase comprise the caspase-specific
prodomain (Figure 2A). In response to a stimulus, the small domain of one procaspase will
homo-oligomerize to the large domain of an identical procaspase to form a heterodimer (17).
Two heterodimers associate to form a tetramer, containing two catalytic sites that appear to
function independently. The conformational change resulting in each domain oligomerization
exposes the aspartate-containing linking regions between the domains (Figure 2B). The linking
regions are proteolytically processed, inducing an additional conformational change which
exposes the linking region between the prodomain and the large subunit on each procaspase
(Figure 2C). Protease hydrolysis of the linking region releases the active caspase tetramer into
the cytosol (Figure 2D). The catalytic domain is formed by the close association of the large and
small subunits, as both subunits contribute residues necessary for substrate binding and catalysis
(18).
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Figure 2: Extrinsic Autocatalytic Activation of Procaspase-8 Two caspase-8 proenzymes
orient the prodomains on the intracellular membrane in response to a stimulus (A). The small
domain (20 kD) of one procaspase heterodimerizes with the large domain (30 kD) of the other
procaspase. The migration of the small subunit induces a conformational change exposing the
aspartic acid-containing linking region between the large and small domains. The conformational
change exposes the catalytic cysteine residue in the binding pocket which cleaves the linking
region, isolating the subunits and exposing independent catalytic residues on each heterodimer
(B). The tetramer is cleaved from the prodomain backbones (C) releasing the active caspase into
the cytosol (D). Adapted from Chang (14).

Caspases recognize and cleave specific small protein sequences of 4 amino acids (19).
The tetrapeptide recognition motif differs among caspases, leading to a differentiation of
caspases by function (20). Procaspases which are first activated by cleavage of the DIS-complex
and c-FLIPL protein contain a tetra-peptide cleavage sequence identical to the motifs on
downstream, inactive caspases. Active initiator caspases will target these effector procaspases for
activation. Procaspases recognize a tetrapeptide sequence, but for many caspases, initiator in
particular, the sequence is the same as the sequence cleaved by the caspase. As such, caspases
will autocatalytically activate additional initiator caspases, or activate effector caspases in a
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cascade effect. Active effector caspases migrate through the cytoplasm of the cell to target and
cleave the particular tetrapeptide sequences on any given protein (21). Caspases inactivate proapoptotic protein inhibitors, destroy cell structures (such as the nuclear lamina of the cell) and
hydrolyze proteins (22). Effector caspases will also cleave and deregulate essential cytoskeleton
proteins such as gelsolin, focal adhesion kinase (FAK) and p21-activated kinase-2 (PAK2),
contributing to the destruction of the cell (23).
In the extrinsically activated pathway of apoptosis, procaspase-8 is incorporated into the
DIS-complex, which releases the initiator caspase-8 into the cytoplasm. The caspase-8 catalytic
site recognizes an IETD (isoleucine, glutamic acid, threonine, aspartic acid) residue on particular
substrates, but can liberally accommodate residues such as isoleucine, leucine and valine on the
first residue of the sequence (24). Reduced specificity of caspase-8 allows for the activation of
downstream caspases with similar tetrapeptide sequences, such as caspase-3. Active effector
caspase-3 recognizes and cleaves aspartic acid-containing tetrapeptides with the highest
specificity for DEVD (aspartic acid, glutamic acid, valine, aspartic acid) (24).

1.4 Degradation Stage of Apoptosis
Apoptosis is morphologically predictable. In the beginning stages of apoptosis, chromatin
condensation and cell shrinkage occur. This is characterized by a smaller cell size and densely
packed cytoplasm (25). As caspase activation continues, extensive blebbing of the cell occurs,
followed by karyorrhexis nuclear fragmentation and separation of cell fragments into apoptotic
bodies during a process called “budding” (2). Apoptotic bodies contain cytoplasm with tightly
packed organelles and some nuclear fragments. The integrity of the organelles is often
maintained within an intact plasma membrane, allowing for future re-use of organelles.
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Phosphatidylserine is secreted on the external surface of the cellular membrane of the fragments
(26). This secretion allows for the recognition of the bodies by macrophages, parenchymal cells,
or neoplastic cells which help to degrade the fragments within phagolysosomes. There is
essentially no inflammatory reaction associated with the process of apoptosis as apoptotic cells
do not release their cellular constituents into the surrounding interstitial tissue and are quickly
phagocytosed (2).

1.5 Detection of Caspase Activation in Jurkat T lymphocytes
Caspases, the key effector molecules in apoptosis, are potential targets for
pharmacological modulation of cell death (27). While caspases and the apoptotic pathways are
well studied, the timing of the activation of caspases is not (28). The knowledge of the timing of
caspase activation could be utilized for the creation of drug therapies that target particular
caspase activation to kill tumorous cells. Currently utilized in research to sensitize resistant
malignancies to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced cell
death, is the design of small target molecules which promote caspase-8 activation (29). The
knowledge of the timing of this particular initiator caspase could assist a medical researcher in
utilizing a caspase-targeted drug therapy to destroy tumor cells with greater efficiency and
accuracy. Such molecules, such as CaspPro, small molecules that promote caspase-8 and
caspase-3 activation, have been experimentally validated to promote the activation of caspases in
tumor cells by neutralizing the cell’s natural XIAP gene- mediated caspase inhibition, leading to
cell death (30). The current approach of regulation of caspase activity, instead of controlling the
activation directly of the caspase, is to use caspase inhibitors to prevent their activation.
However, blocking general caspase activation is ineffective and often results in the eventual
triggering of caspase-independent cell death (31). Therefore, studying the timing of the
10

activation of caspases in individual cells could provide an additional method for researchers to
control the death of anti-apoptotic tumor cells on an individual caspase level.
The timing of caspase activation was previously examined overall in a population of cells
using modified-fluorescence molecular substrates for particular caspase activities to be
identified. Initiator caspase-8 activation occurred collectively at 3 hours post-induction, and
caspase-3 activation occurred collectively at 7 hours post-induction (28). However, observing
caspase activation on a multi-cellular level is only an approximation, and does not provide the
same clear outline of the timing of caspase activation that individual cellular assays could
provide. Microfluidics can be employed as a form of cellular capture to observe caspase
activation on an individual cellular level over time. The microfluidic device allows for the
viewing of suspension and adherent cells in a stable, low-shear force environment (32). This
device designed by Reif et. al., allows for continuous medium supply and waste exchange and
provides a surface for cellular capture (33). The microfluidic devices were created from
poly(dimethylsiloxane) (PDMS) adhered to a glass slide. A glass micro capillary tube was
inserted into a channel that ran down the middle of the PDMS chip and was sealed at the opening
of the channel (Figure 3A). A 30-gauge Teflon tube was attached to the capillary tube for liquid
administration through the channel (Figure 3B). Antibody affinity interactions with the bottom of
the glass slide adhered Jurkat T-lymphocytes, cultured in RPMI, in the channel. Cell viability
was maintained through media flow down the channel and the gas exchange occurring in the
PDMS organic polymer, between the external environment and the cells (33).
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A

B

Figure 3: Microfluidic Devices: Cellular Capture Technique A microfluidic device
composed of a glass microscope slide and a PDMS polymer chip (A). The device chip was
fabricated in an aluminum mold to pour and polymerize the PDMS, creating the 250 µm channel.
The channel ran down the middle of the PDMS and a 200µm capillary tube was inserted and
sealed in place to the device with uncured PDMS, allowing for continuous liquid flow through
the channel. The microfluidic device channels were administered liquids through a 30-gauge
Teflon tube to the glass capillary. The 3mL LEUR LOK syringes were attached through a 200
series barb adaptor (B).

The binding of lymphocytes in the channel occurs through a series of biotinylated
antibody interactions. Biotinylated bovine serum albumin (BSA) was first coated, held to the
slide though electrostatic interactions with the siloxane coating of the glass. Neutravidin is then
coated, noncovalently interacting with the biotin moiety of the BSA, providing the ability to bind
another biotin. Anti-Immunoglobulin M, (IgM) binds the active sites, which binds anti-CD95
(Figure 4) (34). Anti-CD95 is a Fas ligand which binds to the proapoptotic Fas CD95 receptor
(35).
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Figure 4: Affinity Binding in the Channel of the Microfluidic Device The surface of the
channel in the microfluidic device is coated with a series of antibodies which bind Jurkat T
lymphocytes. Electrostatic interactions between the siloxane coating of the microscope slide and
the BSA adhere the protein to the bottom of the channel. Neutravidin binds to the biotin moiety
of the BSA, providing a free spot for the biotin moiety of the anti-IgM. Anti-CD95 is bound to
the anti-IgM which induces apoptosis in the lymphocyte.
As cells enter the coated channel, anti-CD95 binds the pro-apoptotic CD95 receptors. The
microfluidic device allows for consistent liquid flow between 0.15 – 1.5 mL/hr to maintain cell
viability throughout the course of a 6-9 hour assay.
Caspase activity is detected with fluorescence microscopy to examine the temporal
dynamics of apoptosis in Jurkat-T lymphocytes. Rhodamine 110 (R110) is a large fluorescent
molecule, temporarily inactivated with the bis-acylation of the free amide substituent groups.
Conjugation of specific tetrapeptide sequences to R110 results in an nonfluorescent molecule.
This acts as a fluorogenic caspase probe: as caspases cleave the substituted peptides, the free
rhodamine 110 is released, which can be detected at 488 nm.
As caspases become active, they recognize and cleave the aspartic acid-based tetrapeptide
substituents on the non-fluorescent R110 (36). Mono-substituted and free R110 results in
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fluorescence upon excitation with 488 nm laser light (Figure 5) (37). Caspase fluorogenic probes
were created for specific caspases. The (Asp)2-rhoadmine 110 (Z-D2R) derivative has a
covalently bound aspartic acid residue, which is cleaved by any activated caspase that interacts
with the rhodamine molecule, releasing the fluorescent molecule. Due to the small size of the
molecule in relation to the large caspase enzyme, there is no competitive binding. As such, the
amount of fluorescence detected in the cell infected with D2R correlates directly to the amount of
caspase activation (5). The Z addition to the molecule, a phenol group, makes the probe
membrane permeable. Once the probe is cleaved, the Z-group is also removed which reduces the
permeability of the molecule. The (AspGluValAsp)2-rhodamine 110 (Z-DEVD)2R derivative is
substituted with the tetrapeptide sequence (DEVD) which is recognized and cleaved by caspase3, releasing the fluorescent molecule. Therefore, any fluorescence detection correlates to the
activation of the executioner caspase, caspase-3 (36). The third fluorogenic probe,
(IleGluThrAsp)2-rhodamine 110 (Z-IETD)2R, is a Rhodamine 110 derivative, recognized and
cleaved by initiator caspase, caspase-8. Any fluorescence therefore correlates to the activation of
caspase-8 within the cell (38).

Figure 5: Bis-Substituted Rhodamine 110 Cleavage Rhodamine 110 bis-substituted
membrane-permeable fluorogenic probe and subsequent cleavage steps to release free dye
molecule. The bisamide molecule is acylated with aspartic acid residues (D2R) or with and
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aspartic acid containing tetrapeptide sequence recognized by specific caspases ((DEVD)2R,
(IETD)2R). The bisamide molecule does not result in detectable fluorescence (A). As active
caspases cleave the dye molecule, first into the monoamide structure, light detection becomes
possible (B). Spontaneous cleavage of both bis-substituted substituent groups results in the
release of the free dye molecule (C). R110 is detectable at 488 nm.
Fluorescence intensity in the lymphocytes is measured using fluorescent microscopy.
Apoptosis usually occurs within a cell over a period of 6-8 hours (5). In this research, the
fluorescent activity in the lymphocytes, resulting from caspase cleavage of the R110 derivative,
is observed in the microfluidic channel for a period of 6 hours, with activity monitored every 20
minutes. Each experiment examines the timing of a specific caspase activity (or overall activity),
monitoring the intensity of fluorescence with targeted R110 derivative post-apoptotic induction.
Images were taken under fluorescent light throughout the experiment. The images were analyzed
in a software program, Image J, to determine the amount of light that was being given off for
each apoptotic cell. The intensity of light was determined for locations of the channel without
bound cells to establish the background of fluorescence in the channel. The intensity of
fluorescence was determined for cells that were present in the channel but did not undergo
apoptosis and fluoresce. The background was subtracted from these cells and the mean, plus
three times the standard deviation was calculated to establish an apoptotic threshold that could be
subtracted from the background subtractions of each apoptotic cell to determine when caspase
activation was occurring. When detectable fluorescence crossed the threshold, the caspases were
active in the cell (onset time). The duration of caspase activity was determined as the amount of
time the caspase activation remained above the apoptotic threshold. A control experiment was
performed using an non-apoptotic inducing antibody, anti-CD71, to ensure no additional damage
was occurring to the cells from the 488 nm light. There was no observable fluorescence or
damage to the cell.
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In the preliminary 6-hour trials to determine the timing of the overall caspase activity,
caspase-8 activity and caspase-3 activity, the onset time was on average 3.2 ± 1 hours, 2.0 ± 1
hours and 5.0 ± 0.8 hours, respectively. In the general caspase control trials (D2R), the intensity
of the fluorescence stayed above the threshold, plateauing on average near the end of the
experiment. However, a full return of activity to below the threshold was not observed. The short
duration (6 hours) of the trials did not allow a decrease in overall apoptotic activity, concluding
the cellular death process. Therefore, the time course had to be extended to accurately determine
the duration of the caspase activation.
If a time course greater than 6 hours were to be used, the probability of bubbles entering
the microfluidic device channel during the experiment, removing the adhered cells, would
significantly increase, negating the statistical relevance of the experiment. The entrance of air
into the channel is common at the junction where the channel capillary connects the Y-junction;
this can often lead to the formation of a large bubble at the entrance of the channel. As the 3mL
of liquid continues to flow from each of the syringes individually through the tubing and into the
channel, the bubble will accumulate and grow. This leads to obstruction of liquid flow through
the channel and/or the bound cells are removed negating all potential data. Therefore, the
microfluidic devices must be manipulated to better support longer time-courses.
One method to develop caspase-targeted drug therapies would be to manipulate the
timing of the activation of caspases to induce apoptosis in malignant cells. Previous studies have
been conducted in which caspase activity is induced in a tumor cell but the timing of this activity
is unknown. Knowing when caspase activation occurs relative to the process of apoptosis in a
tumor cell, could allow creation of specifically targeted caspase probes and the manipulation of
the timing of caspase activation on an individual level. The goal of this research is to compile a
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complete analysis of the timing of caspase activation post anti-CD95 apoptosis induction in
Jurkat-T lymphocytes. The overall activation of caspases will be determined using the
fluorescent substrate D2R, the activation of the initiator caspase, caspase-8, will be determined
with the (IETD)2R probe and the activation of the executioner caspase, caspase-3, will be
determined using the (DEVD)2R fluorescent substrate. The extension of the experiments to a 9hour time course will allow for the greater-encompassing temporal determination of caspase
activation including an onset time and duration of the particular caspase.
The knowledge of the timing of these caspases could assist a medical researcher in
utilizing a caspase-targeted drug therapy to destroy tumor cells. Such molecules, such as
CaspPro, a small molecule which promotes caspase-8 and caspase-3 activation, have been
experimentally confirmed to promote the activation of caspases in tumor cells by neutralizing the
cell’s natural XIAP- mediated caspase inhibition, leading to cell death (30). The current
approach of regulation of caspase activity instead of controlling the activation directly of the
caspase, is to use caspase inhibitors to prevent their activation. However, inhibition of caspase
activity is ineffective and often results in the eventual triggering of caspase-independent cell
death (31). This current approach could be enhanced by studying the timing of specific caspase
activation and obtaining an overall knowledge of onset times and durations to manipulate
caspase activity on an individual level to oppose anti-apoptotic tumor cells.

17

2. MATERIALS AND METHODS
2.1 Cell Preparation and Culture
The suspension cells, Jurkat T lymphocytes, were cultured in the RPMI 1640 medium
(Hyclone) containing 10% fetal bovine serum (FBS), and 1% penicillin/streptomycin (Fisher
Scientific). Cells were cultured in an incubator at 37 °C and 5% CO2 atmosphere. The cell line
was sub-cultured weekly in a laminar flow hood with a cell biosafety rating sufficient for BSL 2
level cell lines (32).

2.2 Microfluidic Device Fabrication
The microfluidic device was prepared by creating the PDMS top section of the chip,
adhered to a glass slide (Figure 3A). The PDMS was prepared by mixing the
poly(dimethylsiloxane) [1.0g/mL] pre-polymer and the cross-linking agent (Dow Sylgard 184) in
a 10:1 ratio (w/w), purchased together from Ellesworth Adhesives. The solution was mixed
vigorously for 5 minutes. The uncured PDMS was degassed in a vacuum chamber for 20
minutes, until no air bubbles remained. A machined aluminum mold was cleaned with 70%
ethanol, dried, and the polymer was added. PDMS cured in the mold at 80 °C for 2 hours and
cooled to room temperature.
The cured (firmed) PDMS slab had a channel 0.25 mm high, 0.5 mm wide, and 1.5 cm
long. The 19cm slab was cut into approximately 3 cm pieces, and adhered to a glass microscope
slide (76 x 25 x 1mm) (Fisher Scientific). The PDMS was adhered carefully to the glass surface
to prevent blockage of the channel, and was cured at 80 °C for 15 minutes. A 1” length of 220µm
FSPD glass capillary (Trajan Scientific and Medical) was inserted into the channel. A drop of
liquid PDMS was carefully applied to the opening of the channel, on top of the capillary. The
device was cured for an additional 10 minutes at 80 °C. After cooling, uncured PDMS was used
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to seal around the sides of the firmed PDMS to prevent unintentional liquid or gas exchange. The
device was cured for an additional 10 minutes at 80 °C. The device was tested with 70% ethanol
and de-ionized water to ensure no leaks were present by observing the liquid flow as it was
administered to the channel. The channel was washed with 100 µL of 70% ethanol and 100 µL
1X PBS to ensure a clean glass substrate and to remove any excess ethanol before preparing the
channel for cell culture, which would induce cell death.

2.3 Preparation of the Separation Surface
The microfluidic device channel was washed thoroughly with ethanol prior to the
antibody coating procedure, and washed with 1X T50 (10 mM Tris-HCl, pH8, 50 mM NaCl)
buffer to remove excess ethanol. Biotinylated bovine serum albumin (Fisher Scientific) was
coated along the surface of the glass channel, adapted from a procedure described by Flavell
(17). However, the protocol was modified from the Flavell procedure by using neutravidin
(Fisher Scientific) instead of streptavidin to result in greater binding efficiency of the cells to the
glass slide through a reduction of non-specific protein binding (18).
A liquid-administration tube was created from a 3” cut of 30-gauge Teflon tubing (SGE
Analytical Science), inserted 2/3 of the way into a 3.2 mm plastic connector with 200 series
barbs (Cole Parmer Instrument) and glued into place with hot glue. LEUR-LOK tip, 3 mm
syringes (Dickinson and Company) were screwed into the barbed connector. The clean, dried
channel was then coated with biotin conjugated albumin diluted in T50 buffer by pipetting
(1mg/mL) to the end of the channel and pulling the syringe until the protein solution had traveled
the length of the channel at room temperature. An aliquot of 20 µL of 1XPBS was pipetted onto
the open end of the channel to prevent liquid movement, and the device sat for 45 minutes for the
BSA to coat. The protein was removed by pushing air through the tubing with an empty syringe,
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and was then washed with 1X T50 buffer. This was repeated an additional time, and the channel
was dried. To the dried channel, 30 µL of Neutravidin in T50 buffer (0.2 mg/mL) was applied to
the channel (in the same protocol as BSA), and coated for 20 minutes (Fisher Scientific).
Devices coated with BSA and Neutravidin could be stored at 4°C for up to 2 months. The day of
the experiment, 20µL of anti-IgM in PBS (25µg/mL) was coated to the channel (following the
same procedure as BSA) for 20 minutes and washed with T50 buffer. Functional anti-CD95 in
PBS (50 µg/mL) was coated to the channel for an additional 20 minutes (in the same procedure
as BSA) (Fisher Scientific). The device was washed with de-ionized water and 1X PBS. All
microfluidic devices were used on the same day that the IgM and anti-CD95 were coated and
prepared.

2.4 Y-Junction Tubing Fabrication For Fluid-to-Channel Administration
Two lengths of 30-gauge Teflon tubing (SGE Analytical Science), were cut to
approximately 12 and 14 inches in length using a razor blade. The end of each of the tubes was
secured into a plastic connector with 200 series barbs (1/8”, 3.2 mm) (Cole Parmer Instrument),
with hot glue as previously described. A razor blade was used to slice the ~14” Teflon tube down
the diameter to half the length, ~3 cm from the non-sealed end. A capillary of 150 µm was cut ~8
cm in length, and was thread through the incision, into the shorter end of the tubing, until only
~3 cm remained (Figure 6A). The free end of the ~12” tubing was inserted onto the larger
portion of the glass capillary inserted in the junction. The small, flexible capillary allowed for the
optimization of the junction by holding the tubing in place as hot glue was applied to each side.
A tighter seal could then be obtained at the junction, reducing fluid pressure which would
prevent backflow and leakage (Figure 6B). The junction was tested with DI water and 70%
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ethanol to ensure there were no leaks. The capillary was removed from the remaining end prior
to testing of the junction

A

B

Figure 6: Fabrication and Design of 30-Gauge Teflon Y-Junction Creation of the Yjunction involved two cuts of 30-gauge Teflon tubing, for which one end was inserted into an
incision made in the opposite tube with a razor blade, and held in place with a thin, 150 µm
capillary, sealed with hot glue(A). The small capillary was removed from the junction prior to
testing. The Y junction allowed for simultaneous administration of liquids from two different
syringes into the microfluidic device through the course of the experiment (B).
2.5 Cell Capture and Detection
Prior to each experimental analysis, individual aliquots of Jurkat T-lymphocytes (5 mL) in
RPMI were transferred into four 1.5 mL centrifuge tubes and spun at 4000 rpm for 5 minutes in
an Eppendorf microcentrifuge 5425 (10 cm radius) at room temperature. The cells were washed
with 1X PBS, and centrifuged for an additional 5 minutes at 4000 rpm before finally being
concentrated in 1 mL of PBS. Cells were administered into the microfluidic channel at the start
of the experiment for capture and induction of apoptosis.
The microfluidic device was taped down on the stage of the inverted microscope (Eclipse
Ts2R-FL). The Y-junction created from the 30-gauge Teflon tubing was attached at the single
junction to the capillary in the microfluidic device. The Y portion, the tubing on the opposite end
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of the junction, was used to attach the syringes with the necessary reagents to be flowed through
the channel during the experiment.
Prior to the cell loading process, the fluorogenic probe solution was created from 3 mL of
1X FBS- 1X PBS solution, adding 6 μL (20µM) of the experimental fluorogenic probe
suspended in DMSO. This solution was pipetted into a clean, sterile syringe. Preparation of all
antibodies and probes was conducted in a laminar fume hood. The solution was administered to
the syringe for immediate use. Another syringe was prepared containing the re-suspended Jurkat
cells in PBS. A third syringe was prepared from 3 mL of 1X PBS, prepared at the start of each
experiment.
The syringe containing the FBS-PBS-probe solution was attached to one connector on the
Y-junction, and the cell syringe was attached to the other (Figure 7). Both syringes were
mounted on an automated syringe pump (Kd Scientific). FBS-PBS was flowed through the
channel at a rate of 1.5 mL/ hour. Cells were flooded through the channel at 1.5 mL/ hour. The
syringe containing PBS was exchanged for the cell syringe, and PBS was pushed through the
channel at 1.5 mL/ hour to remove excess cells from the tubing. All pumps were stopped, and the
cells settled for 20 minutes. The channel was then rinsed to remove un-adhered cells with FBSPBS at a rate of 1.5 mL/ hour for 3 minutes, then washed with PBS at 0.2 mL/ hour for 5
minutes. A white light image (exposure=25 ms, DIA filter, Phase contrast 2) was taken. Then,
with the 100-W Hg lamp and green light filter, (exposure = 1000 ms) a fluorescent image was
taken to determine the fluorescent emission from apoptotic cells. White and green light images
were taken every 20 minutes for 6 hours, alternating FBS-PBS flow for 15 minutes at 0.2 mL/
hour and PBS flow for 5 minutes at 0.2 mL/ hour (Figure 8). All images were taken with a 20X
objective using a Nikon Monochrome Microscope Camera (DS-Ri2). The software from the

22

instrument manufacturer produced images in the 16-bit tagged image file format. The images
were processed in ImageJ (v. 1.41, National Institute of Health) (19).

Figure 7: Temporal Dynamics Experimental Procedure Experimental set up consisting of a
microfluidic device taped to the stand of an inverted microscope. A Y-junction of 30-gauge
Teflon tubing connects the device to two syringes docked on automated syringe pumps to
dispense liquid at a constant rate during the experiment.

A

B

Figure 8: White Light and Green Light Images: Image J Analysis A white light image
(10X magnification, 25ms exposure) and a green light image (10X magnification, 1000 ms
exposure) of the microfluidic device channel. Jurkat T lymphocytes were adhered to the bottom
of the channel through affinity interactions to the anti-CD95 on the channel. The software
processing system Image J is used to identify the location of a cell on the white light image (red
circle A) through pixilation coordinate-system to determine the fluorescence intensity of that
same cell in the green light image (red circle B). Scale bar represents 100µm.
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2.6 Cell Analysis
From each experiment, two sets of images were obtained (white light and green light)
(Figure 8). Using Image J, each set of images was stacked into a single image file in order to
monitor fluorescence intensity of individual cells over the course of the experiment. The image J
plugin, MeasureStack, was used to determine the background of fluorescence in the microfluidic
device by obtaining intensities from locations all across the channel that did not contain cells for
the duration of the experiment (20). The intensity of fluorescence was determined for each cell
from the stack, and the backgrounds were subtracted to create an apoptotic threshold for caspase
activation.
2.7 Safety Considerations
The Jurkat T lymphocyte cell line is a biosafety level 1 organism that was handled in a
laminar flow hood for sub-culturing. Universal precautions for bloodborne pathogens were
observed at all times. Samples containing cells and other contaminated materials were placed in
a biohazard container and properly disposed of. The ethanol used in this research was 70%
ethanol and was benzene-containing. Ethanol is highly flammable and was kept away from open
flames at all times (33). DMSO was used to suspend the fluorogenic probes. DMSO is
membrane-permeable and may enhance the absorption of numerous chemicals into the skin. It
was handled following sterile procedure and used only in the biosafety hood (34). The 3mL
LEUR LOK syringes were purchased without needles so sharps disposal was not necessary.
Laser fluorescent lights were secured within the microscope at all times to prevent eye injury or
damage.
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3. Results and Discussion:
3.1 General Caspase Activation Determination
In order to approximate a timeline for the activation of all caspases within the Jurkat-T
lymphocytes, a microfluidic device was fabricated. The chip was coated first with biotinylated
BSA, followed by neutravidin, biotinylated anti-mouse IgM, and lastly anti-CD95. The bisaspartic acid substituted rhodamine 110 fluorogenic probe (D2R) was used in these control trials,
as the terminal aspartic acids are non-specifically recognized and cleaved by any and all
activated caspases within the cell. A sample of Jurkat cells suspended in 1X PBS was
administered to the device channel after initial rinsing with the fluorogenic probe-FBS solution.
Liquid flow to the channel was ceased for 20 minutes to allow the cells to settle and bind to the
antibody-coated surface. This resting period is necessary to allow proper antigen binding without
disruption from liquid pressure flow. If this step is not followed, the binding of anti-CD95 may
not occur with the CD-95 receptors on the membrane and the spontaneous induction of apoptosis
may not occur (38). The channel was then washed with the probe solution at 1.5 mL/hr to clear
excess cells from the channel. As the (Z-D)2R molecules are membrane-permeable, they will
permeate the membrane resulting in the intracellular cleavage of the substituted tetrapeptide
sequences, releasing the fluorogenic monosubstituted and disubstituted Rhodamine 110
molecules (40). The zwitterion R110 is less membrane permeable and is known to accumulate
within the cells. Extracellular Rhodamine 110 must be vacated from the channel to ensure the
reduction of background in the green-light filtered image. To clear extra-cellular, inactive probe
from the channel, PBS was washed through the channel at a rate of 0.20 mL/hr for 5 minutes.
Following the rinse, a white light image was taken at 10X magnification with an exposure of 25
ms, yielding the first white light image, “0.0”. Immediately, the exposure was changed to 1000
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ms and second image was taken, providing the first green light image of the time course (Figure
8).
White light and green light images were taken with the respective microscope settings
and exposures, every 20 minutes, for 6 hours. After the image was captured, the probe solution
pump was turned back on at a rate of 0.20 mL/hr for 15 minutes, followed by a 5-minute rinse
with 1X PBS to clear inactive fluorogenic probe from the channel.
The obtained images for each set of data, white light and green light, were overlaid to
create image stacks to trace cell fluorescent activity with program Image J. With a pixilationcoordinate system, the white light stack was used as a map to determine the location of
background and cell locations in the green light stack. The MeasureStack plugin was used to
determine several locations from all over the surface of the channel that did not contain adhered
cells and obtain the intensity of fluorescence. The fluorescence intensities of non-fluorescent
cells across the channel were determined, tracing a circle around the cell through the green light
stack. The background of each correlating time-image was subtracted from the non-fluorescent
light intensity. The background-subtracted fluorescence values were averaged for each phototime respectively and the apoptotic threshold was established by adding three times the standard
deviation of each average in order to determine the limit of detection. Each cell was tracked for
the duration of the experiment, measuring the fluorescence intensity through the green light stack
(Figure 9).
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Figure 9: Tracking Apoptotic Cells through the Time Course White light images (10X
magnification, 25ms exposure) and green light images (10X magnification, 1000 ms exposure)
of the microfluidic device channel over the course of the experiment. The location of the cell in
the channel is determined from the white light image, and the amount of fluorescence given off
by that cell is detected in the green light image. The amount of fluorescence is shown to increase
in a particular cell over the course of the experiment. The visible shrinkage of cells in the white
light images is due to the associated morphological changes of a cell within the apoptotic
process. The purple circle indicates the trace of the fluorescence of a single cell over the time
course. Scale bar represents 100 µm.

The intensity of background fluorescence was subtracted from the intensities obtained
from the fluorescent cells, and an apoptotic threshold was established and subtracted to
determine the amount of caspase activation occurring over the 6-hour time course. Cells with
threshold values greater than zero were considered to have active caspase activity above the
apoptotic threshold. The onset time, when the threshold activity crosses the x axis of caspase
activity, and the duration, how long the threshold remained above the x axis, were determined for
each fluorescent cell in the time course. In Figure 10, the intensity over the 6 hours is shown for
4 individual cells. The onset time and duration were traced for ~100 cells (data not shown), and
the resulting onset time and durations were traced for each to approximate of the timeline of
caspase activation in the cell.
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Figure 10: Experimental Analysis: General Caspase Activation The background subtracted
fluorescence intensity (A.U), of 4 Jurkat-T lymphocytes cells over 6 hours using D2R probe to
monitor activation and determine onset time and duration. The subtraction of the background and
the calculated apoptotic threshold determined if caspase activation was occurring in the cell.
Subtracted intensities greater than zero, signified the activation of caspases within the
lymphocyte. The onset time occurs when fluorescence intensity becomes positive, and the
duration is the amount of time the fluorescence remains above the threshold. General caspase
activation had a mean onset time of 3.2 ± 1 hours and an approximate 150 ± 80 minutes of
duration. Apoptotic activity does not return to baseline.

The cells that fluoresced with administration of D2R were used to establish a baseline of
all caspase activity within the cell. From the fluorescence intensity, the overall onset time and
duration could be obtained. The average onset time of activation was 3.2 ± 1 hours, and the
average duration of apoptotic activity was 150 ± 80 minutes (Table 1). The mean and median
comparison values were determined for each of the categories (onset time and duration) from the
experiments. While the values were similar, the means are reported for the average onset time
and durations, comparable by their standard deviations (Table 1). From this preliminary
approximation of the timing of caspase activation, it was hypothesized that the DISC formation
and subsequent homo-oligomerization or hetero-oligomerization of procaspase-8 by c-FLIPL was
occurring between the initial binding of the pro-apoptotic ligand antiCD-95 at time zero and 1.8-
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2 hours (13,14). These procaspases contain a tetra-peptide sequence which match that of the
cleavage sites on additional downstream caspases. When active caspase-8 is released into the
cytosol, it will activate target effector procaspases in a cascade form or continue to activate
additional procaspase-8 molecules (21). This active caspase-8 release into the cytosol is thus
hypothesized to occur 2 hours post-ligand binding. However, if the duration were to also be
determined, it would be hypothetically shorter than the duration of the general caspases. While
the active caspase-8 enzymes can autocatalytically activate additional procaspase-8s, their
primary role is to activate the effector caspase zymogens (caspase-3) (21). The caspase-8
catalytic site will recognize the IETD sequence on particular substrates, but has the ability to
accommodate residues such as leucines and valines (24). Due to this reduced specificity in the
binding pocket of caspase-8, the downstream activation of the executioner caspase occurs
(caspase-3). Caspase-3 activity leads to the recognition and subsequent cleavage of higher
specificity DEVD residues, including procaspase-3 and additional zymogen executioner caspases
(24). The effector caspases will inactivate the normally active apoptotic inhibitor proteins,
inducing apoptotic changes, destroying cell structures and deregulating functional proteins (21).
As the activity of the executioner caspases increases, the need for initiator procaspase activation
decreases and therefore procaspase-8 cleavage diminishes. As such, it could be hypothesized that
employing an executioner caspase- targeting fluorogenic probe such as (DEVD)2R would result
in an onset time of a much later time in the time-course. As the caspase cascade was predicted to
occur between 6 -8 hours, the delayed onset time would also result in a shorter duration of
activation (5).
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Preliminary (6 Hour) Temporal Dynamics of Caspase Activation: Mean Onset Time and
Duration
Fluorogenic
Caspase
Probe

Median
Onset Time
of Caspase
Activity

Mean Onset
Time of
Caspase
Activity

Standard
Deviation of
Means

Median
Duration of
Caspase
Activity

Mean
Duration of
Caspase
Activity

Standard
Deviations
of Means

D2R

3.0 hours

3.2 hours

1 hours

150 minutes

150 minutes

80 minutes

2.0 hours

2.0 hours

1 hours

180 minutes

180 minutes

50 minutes

5.3 hours

5.0 hours

0.8 hours

40 minutes

47 minutes

30 minutes

(n=122)

(IETD)2R
Caspase-8
(n=73)

(DEVD)2R
Caspase-3
(n=100)

Table 1: The mean onset times and durations for the caspase activities determined from each of
the fluorogenic caspase probes used in the 6-hour time course (D2R, (IETD)2R and (DEVD)2R).
The fluorescence of ~100 fluorescent cells were traced using each probe. The onset times and
durations were determined for each cell individually. The mean was then taken for each data set
(onset time, duration).
It should be noted that the general caspase activation is an approximation of the caspase
activity. Figure 10 shows the fluorescent cells tagged with the D2R probe and their intensity of
fluorescence over the 6-hour period. The intensity of fluorescence rises as the caspases become
active within the cell; however, a decrease in the slope does not occur. This suggests that the
level of caspase activity does not diminish by the end of the 6-hour time course and that a further
extension trial would need to be conducted in order to determine the end of the duration of the
caspase activation (5).
3.2 (IETD)2R: Initiator Caspase Activation Determination
To determine the specific timing behind the initial activation of caspases within the cell,
an identical experimental procedure used for D2R was conducted using the (IETD)2R fluorogenic
probe. Analysis of the green and white light images in Image J resulted in an average onset time
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of 2.0 ± 1 hours and a duration of caspase activity of 180 ± 50 minutes (Figure 11) (Table 1).

Figure 11: Examination of General Caspase and Initiator Caspase Temporal Activity The
average onset time and duration of the general caspases activation (D2R) and the initiator caspase
activation ((IETD)2R) was measured for the period of 6 hours. The resulting fluorescence
intensity (A.U) was background subtracted to determine the apoptotic threshold. Fluorescence
intensity greater than 1 was considered to be “apoptotic” with active caspase activity. General
caspase activation began at 3.2 ± 1 hours on average and lasted for a duration of (150 ± 80
minutes). Initiator caspase began at approximately the same time (2.0 ± 1 hours post induction)
and lasted for 180 ± 50 minutes.
These findings were congruent with the literature preliminary apoptosis assay which
determined that caspase-8 activation within a population of cells, detected using modifiedfluorescence microscopy, occurred collectively at 2-3 hours post-induction (28). Observing
caspase activity at the population level is an approximation of enzyme activity. Differing
catalytic rates of the apoptotic-inducing Fas ligand binding to CD-95 Fas receptor result in the
potential for caspase onset activation to vary (12, 38). Therefore, an individual cell analysis of
the caspase activation is necessary to gather a more precise look into the temporal dynamics of
the initiator caspase activation.
As the procaspase-8 autoactivation was occurring, resulting in the cleavage of the
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(IETD)2R probe, the resulting fluorescence directly correlated to the caspase-8 activation
occurring within the cell (41). The 6-hour time course study confirmed the hypothesis that initial
caspase activation is due to the activation of the initiator caspases, as the onset time from the
(IETD)2R trials was equivalent to the onset time from the D2R trials. The duration of activation
of the (IETD)2R-tagged cells was significantly shorter than the overall duration for general
caspase activation, illustrating the effect that the executioner caspases must have in terms of the
final caspase activity. As initiator caspase activity is diminished, the (IETD)2R fluorescence
stops being generated. The control (D2R) trials still show prevalent caspase activity occurring
within the cell, because executioner caspases are active and cleaving within the cell. As a result,
the mean onset times for the D2R and the (IETD)2R time courses are nearly the same, but the
durations are longer for the general caspase probe, D2R (Table 1).

3.3 (DEVD)2R: Executioner Caspase Activation Determination
To determine the timing of executioner caspase activation in the lymphocytes during the
degradation segment of the caspase cascade, the previously described experimental procedure
was conducted using the (DEVD)2R fluorogenic probe. Following analysis in Image J, the mean
onset time and duration were determined to be 5.0 ± 0.8 hours and 47 ± 30 minutes, respectively.
Shown in Figure 12, the timing of the executioner activation starts after the initiator caspase
activation as hypothesized (Table 1).
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Figure 12: The temporal dynamics of the caspase activity was monitored over the period of 6
hours. General caspase activation was monitored with the aspartic-acid bis-substituted fluorogenic
probe (D2R), the initiator caspase activation (caspase-8) was monitored with the (IETD)2R
fluorogenic probe, and the executioner caspase activation was monitored with the (DEVD)2R
probe. Preliminary studies approximated caspase activity onset times of 3.2 ± 1 hours for general
caspase activation 2.0 ± 1 hours for initiator caspase activation and 5.0 ± 0.8 hours for executioner
caspase activation (A). The durations were also determined and found to be 150 ± 80 minutes for
general caspase activation, 180 ± 50 minutes for initiator caspase activation and 47 ± 30 minutes
for executioner caspase activation (B). It should be noted, however, that, due to the restricted
timing of this experimental procedure, a true downward slope was not observed for the executioner
and general caspase activation. Therefore, these trials were simply an approximation of the
duration and extension trials would need to be conducted.
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Once procaspase-8 is cleaved and activated within the cytosol, the molecule will
recognize and cleave IETD peptides within the cell. However, due to reduced specificity in the
binding pocket to isoleucine and valine, the sequence DEVD (introducing a substitution of the
N-terminal isoleucine group with an aspartic acid and the third threonine residue for a valine
residue) may also be recognized and cleaved with a reduced affinity (24). The fluorescence
resulting from the addition of the Rhodamine 110 bis-substituted probe (DEVD)2R therefore is
directly correlated to the activity of caspase-3 within the cell (39).
Preliminary apoptosis assay results had previously determined that caspase-3 activation
within a population of cells collectively occurred at 7 hours (5). However, due to the sensitivity
of the microfluidic devices, the knowledge that 6 hours was the bottom of the average that the
caspase activation would occur, and understanding the error in recording caspase temporal
dynamics as a collective of cells rather than independent analysis, a 6 hour time course had been
originally selected (5,28).
Caspase-3 was predicted to have a later onset time due to the necessary activation of the
initiator caspases first (6). As a greater number of executioner caspases become active,
procaspase-8 cleavage would reduce due to a feedback response. Subsequently, the activity of
the initiator caspases would hypothetically diminish as the executioner caspase activity
increased, initiating the effector phase of apoptosis.
As seen in the 6-hour time course, as the initiator caspase activation begins to decline,
there is a steep rise in the amount of executioner caspase activation, further supporting the
hypothesis of the roles that these caspases play in the activation process. The short duration
period of the executioner caspase activity is attributed to a short experimental duration that did
not allow for the executioner caspase activity to return to baseline as shown in Figure 12.
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While it was known that the caspase cascade would terminate within 6-9 hours postligand induction, the fabrication of the microfluidic devices was very temperamental, often
resulting in device failures before the termination of the experiment (5). As such, a 6-hour time
course was used as the initial time selected to observe the temporal dynamics of the caspase
activation in this study.
Being the key effector molecules in apoptosis, caspases are potential targets for
pharmacological modulation of cell death (27). Understanding the timing of the caspase
activation within the cell could aid in the development of a caspase-targeted drug therapy to
destroy tumor cells with a greater accuracy and efficiency. CaspPro are small molecules which
promote caspase-3 activation in tumor cells by neutralizing a natural executioner inhibitory
caspase (30). However, with the full knowledge of the temporal dynamics of the caspase-3
activation, the onset time, length of duration, and cessation of activation, a targeted and specific
drug therapy could be designed and utilized against anti-apoptotic tumor cells. Repeating the
experimental trials with an extended time course to the full 9 hours of the expected duration of
caspase activation could provide a more detailed account of the exact duration of the executioner
caspase activity.

3.4 Extension Analysis: Microfluidic Device Refashioning
In order to determine a more accurate duration of caspase activity, the experimental
procedures were repeated for each of the fluorogenic probes. However, this series of experiments
had an extended time course of 9 hours, compared to the original 6 hours. As apoptosis most
commonly occurs within a period of 6-8 hours in Jurkat T-lymphocytes, the addition of time to
just outside the length of the normal apoptotic duration could allow greater visualization of the
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caspase activity (5). This addition of time was designed to allow for the activity of the
executioner caspases to reach a maximum and return to baseline and obtain an accurate depiction
of the temporal dynamics of the caspases within the extrinsic pathway.
It should be noted that in the non-extension trials, a successful experiment resulted on
average once for every four experiments performed (~25% success rate). A successful
experiment is designated as one in which the Jurkat cells bound to the bottom of the channel
through the affinity interactions, specifically to the CD95 for the spontaneous extrinsic induction
of apoptosis, and were adhered in place for the duration of time course (38). This very low
success rate was mostly due to structural issues in the fabrication of the microfluidic devices.
In the construction of the microfluidic devices, there are several key factors which are
required to obtain a device that would produce a successful experiment. First, when the
microfluidic device is first peeled from the mold, it must be cleaned with 70% ethanol, and dried
thoroughly. This is to ensure that there are no residual dust particles between the PDMS chip and
the glass slide that would prevent the tight seal between them. When the non-cured PDMS is
applied to the PDMS prior to adherence to the glass slide, it must be applied directly along the
line of the channel, but without encroaching upon the channel (Figure 13A). This will prevent a
tight seal around the channel and allow for liquid to flow though the PDMS instead of down the
affinity-bound surface. Too little or too much of the PDMS near the channel will result in an
improper seal and lead to a faulty device (Figure 13B). This flow of liquid would cause the
dissociation between the PDMS and the glass slide, preventing the cells from entering and
remaining in the channel and therefore rendering the experiment unsuccessful.
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Figure 13: Extension Experiments: Ranking System for Enhanced Microfluidics
Performance A ranking system was established for the creation of the microfluidic devices in the
extension trials. Due to the fragility of the extension experiments, microfluidic device creation was
refined and adapted to support the time extension. Introduction of glass capillaries of a greater
diameter, 320 µm, was used in these devices to allow for reduction of the liquid pressure entering
the microfluidic device channel. The ranking system was based on overall sustainability with
induced liquid flow, resistance to bubble formation, and longevity of the created channel. A device
ranked “1” was considered an “Experimental Device”, had a clean seal along the channel, and no
PDMS encouraging upon the capillary or channel (A). Air pockets and open spaces along the seal
of the channel inhibit liquid flow and promote bubble formation. The devices were ranked
accordingly (B). Devices in which liquid flow was inhibited were ranked higher and were
considered unusable (C). For the extension trials, devices ranked 1 and 2 only were employed.

Second, when the capillary is first inserted into the channel of the device, it must be
inserted directly parallel to the glass slide into the channel without puncturing the wall of the
channel or obtaining any residual PDMS on the tip of the capillary. If the capillary is
contaminated on the tip with PDMS, liquid flow may be blocked, rendering the device useless
(Figure 13C). Furthermore, if PDMS is scraped from the side of the channel by the capillary tip,
PDMS can also be introduced into the channel in this way and inhibit liquid flow in the same
manner as the device in Figure 13C. This can also cause PDMS to partially dislodge from the
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side of the channel. In this event, liquid flow may occur, but the PDMS fraction may not
completely dislodge until several hours into the time course. This may lead to bubble formation
later on in the experimental trial, preventing liquid flow, and rendering the data non-viable
(Figure 14). Introduction of a bubble into the channel post-affinity binding of the cells to the
channel, will inhibit medium flow, starving the adhered cells of the proper nutrients, and leading
to the disruption of the antibody binding (32). Therefore, prevention of bubble introduction into
the channel during the experiment is a great consideration in the fabrication of these devices.

A

B

C
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Figure 14: Disruption of adhered cells in the channel by introduction of a bubble. White light
image (10X magnification, 25 ms exposure) of the Jurkat T lymphocytes adhered in the channel
after 20-minute adherence period with CD-95 affinity interactions prior to the introduction of a
bubble (A). A bubble passing through the microfluidic device channel (Figure 3) after introduction
through improper sealing of the microfluidic device (B). The same section of the channel as
presented in (A), yet after the clearance of the bubble from the channel (C). Most of the cells have
been disrupted in their affinity bindings and fled the channel. Scale bar represents 100 µm.

Once the capillary has been inserted, it must be properly sealed to prevent bubble
formation at the junction of the capillary and the channel, and to allow for tubing to be attached
to the distal portion of the capillary to allow fluid administration. The seal is obtained by
dropping un-cured PDMS onto the opening of the channel where the glass capillary is inserted. It
must be noted that the addition of this un-cured PDMS must be done very carefully to prevent
the inhibition of liquid flow through the capillary. If the device is tilted following the application
of the liquid PDMS, the polymer may enter the channel and clog the capillary and entrance. This
would render the device non-viable. By pipetting the sealant PDMS onto the capillary entrance
while the device was still in the oven allowed for the reduced probability of PDMS entering the
channel and inhibiting liquid flow.
Finally, in the process of manufacturing of the devices, the sides of the PDMS-mold
cutting must be sealed onto the glass slide. This is to prevent the PDMS from dissociating from
the slide, and to create a seal which will allow the dissipation of gaseous wastes from the cells to
the external environment, while still allowing the internal flow of oxygen (36). Improper sealing
of the sides can induce microtears in the PDMS and also result in the improper connection
between the slide and the PDMS, allowing for liquid to flow out of the channel and into the body
of the device (Figure 13B). This would render the device unusable as the cells would not be
receiving the medium maintaining their viability. In sealing the sides, the uncured PDMS must
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be administered down the length of the PDMS cut out, and across both the top and bottom
shorter widths of the chip. As the PDMS is applied, it is important that it be applied in a very
light layer to prevent the addition of uncured PDMS into the channel, blocking the opening as
described previously in the sealing process. If PDMS is administered to the back of the channel
(distal end without capillary inserted) in an attempt to seal, but spreads to the inside of the
channel, a cut out can be made of the clogged end (Figure 15A). Any residual PDMS that is in
the back of the channel when the cut-out is made will induce blockage and prevent the flow of
liquid through the channel. This may result in a buildup of liquid at the distal portion of the
microfluidic device channel which can interfere with the cell-antibody binding affinity and
disrupt the experiment (Figure 15B). Therefore, it is important that the PDMS not be present in
the back of the channel, and that if a portion needs to be removed from improper application of
the un-cured PDMS, then it must be scraped out along the sides and down the class to ensure no
particles remain that may trap bubbles and hinder liquid flow.

A

B

Figure 15: Microfluidic Device Repair: Attempts at Increasing Device Longevity Attempts
at repair of a microfluidic device to enhance performance and reduce bubble formation. During
the sealant process in the fabrication of the devices, if PDMS enters the distal end of the channel,
a cut out can be made of the clogged portion to still allow for use of the channel in the
experiment (A). However, the cutting process must be very precise, or it can lead to bubble
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induction. If all PDMS is not scraped from the bottom and periphery of the slice made at the
back of the channel, fragmented PDMS will remain in the channel and promote bubble
adherence and formation. The figure shows a bubble which is beginning to grow on the cut out
end of the microfluidic device (B). Scale bar represents 100 µm.
A ranking system was established for the microfluidic device based on their overall
sustainability with induced liquid flow, resistance to bubble formation, and longevity of the
created channel (Figure 13). Several characteristics were examined: precision of the application
of un-cured PDMS to adhere the PDMS chip to the glass slide, the quality of the seal of the
PDMS to the glass slide and seal of the capillary into the channel, the facilitation of liquid
movement through the device channel and the overall bubble-formation capability that the device
possessed. Devices were ranked on a numerical scale (1-5), in which a ranking of 1 was
considered a “Experimental Device”, while a ranking of 5 was considered “Unusable”. A device
marked as 1 would have a smoothly sealed channel which would antagonize bubble formation
(Figure 13A). The last ~2 cm of the capillary in these devices was sealed into the device, with a
clean seal and the glass slide did not have PDMS on the bottom of the slide which could affect
the visual orientation of the slide under the microscope and alter the dynamic of the fluorescence
analysis (Figure 13A). Devices which contained PDMS in the channel, did not have a proper
seal, or experienced leakage were ranking accordingly (Figure 13B-C). Only devices ranked 1 or
2 were utilized in the experimental procedure. One batch of devices (one mold equivalent)
resulted in 6 devices, each PDMS cutting ~1.25” in length. With luck, one device from each
batch was considered to have a sufficient experimental ranking. As such, the precise design of
these devices renders them extremely tedious and highly susceptible to failure. Therefore, when
the need for extension trials was determined, the need for refinements to the devices became
prevalent.
In order to create a microfluidic device that could withstand the additional 3 hours to the
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time course and allow for proper flow of liquid through the channel, several adjustments were
made to the design process. First, glass capillaries with a larger diameter (300 µm) were
substituted for the 220 µm capillaries. This was in an attempt to increase the volume for the
liquid to flow to reduce back pressure in the Y junction and at the device junction point. With
this increase in size, the tubing also needed to be increased in diameter, which would
subsequently decrease the back-flow pressure through the tubing. The use of the thicker
capillaries made the fabrication of the devices more tedious. Due to the increased surface area of
glass capillary being inserted into the channel, the likelihood of the pointed tip of the capillary
scraping the inside of the channel increased. Therefore, these devices needed to be manufactured
with a greater amount of care and precaution. As expected, the rate of success in the fabrication
of these devices was decreased from the initial rate, to nearly one “Experimental Device [Rank
1]” per every two batches (12 devices).
A new design for a Y junction also had to be incorporated into the experimental
procedure. In the previous Y-junction design, the wall of the tubing was thin, allowing for a
junction to be created by a simple incision in one of the tubing walls (Figure 6). However, due to
the increased thickness of the capillary walls, this same design structure was not possible, and a
simple incision and insertion would result in a T-shaped junction which would allow for
backflow and unequal liquid distribution into the microfluidic device (Figure 16A). Therefore, a
junction was created in which one end of the 14-gauge tubing was sliced into a point, and
inserted into a partial incision in the second 14-gauge tubing, using the small-capillary insertion
method previously described (Figure 16B-C) (Figure 6). This allowed for even liquid distribution
and flow from each syringe into the microfluidic device.
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Figure 16: Fabrication and Design of 14-Gauge Teflon Y-Junction Creation of the thick
tubing (14-gauge) Y-junction. The Y junction is made in the same fashion as the smaller gauge
tubing (30-gauge); however, due to the increased surface area of the tubing that would be inserted
into the incision in the opposite tube, the end of the tubing needed to be cut into a point with the
razor blade prior to insertion with the 220µm capillary (A). The thick tubing Y junction was then
created by inserting the cut end of the tubing onto the capillary and hot gluing the junction (B).

Determining the flow rate of the syringes for the experiment was another barrier in the
extension trials for the caspase activation determination. In the non-extension trials with the 220
µm capillaries, the flow rate was set at 0.20 mL/ hour for each syringe. However, with the
increased surface area of the new capillaries, the force of the liquid flowing over the cells would
be increased if the rate were maintained. In the initial extension trials the rate was reduced to
0.15 mL/ hour for both syringes. However, it was found that the extracellular rhodamine 110
molecules were not perfused in a sufficient amount of time to capture a non-background
disturbed image (32). The flow rate was thus increased to 0.25 mL/hour as the standard flow rate
for the PBS syringe, and the FBS-probe syringe pump was set to 0.15 mL/hour. The overall
success rate of the extension trials, success defined as a microfluidic device that was coated with
anti-CD95 was used successfully through a 9-hour time course without, or with minimal bubble
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proliferation, was 25%, resulting in mostly failed experiments. However, ~100 (statistically
comparable) cells were obtained from each respective extension trial with the fluorogenic
probes.

3.5 Extension Analysis: D2R, (IETD)2R, (DEVD)2R
The newly fabricated devices were employed to obtain an overall picture of the caspase
activation that was occurring within the lymphocyte for an extended period of 9 hours, using the
D2R fluorogenic probe. The mean onset time remained consistent, as expected, of 2.4 ± 0.6 hours
yet with a new duration of 360 ± 60 minutes (Figure 17) (Table 2).

A
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Figure 17: An All-Inclusive View of the Temporal Dynamics of Apoptosis in Jurkat Tlymphocytes In the extension trials, caspase activation was monitored for general caspase
activity (D2R), initiator caspase activity ((IETD)2R) and executioner caspase activity
((DEVD)2R). The average onset times were found to be 2.4 ± 0.63 hours, 1.8 ± 0.8 hours and 5.2
± 1 hours post-affinity binding respectively for each fluorogenic probe (B). The average
durations of each were determined to last 360 ± 60 minutes,120 ± 40 minutes and 130 ± 60
minutes post induction (C). The activity of the caspases returned to below the apoptotic threshold
by 7.3 hours on average. Therefore, the cessation of caspase activation was able to be fully
visualized.
The increased duration of the caspase activation implied that the previous hypothesis, in
which 6 hours was not a sufficient quantity of time to monitor complete caspase activation, was
confirmed. The extended time course indicates that caspase activation, theoretically the extrinsic
caspase activity, was occurring within the cell until approximately 7.3 hours. Due to the roles of
initiator and executioner caspases, it was theorized that this latent activity past the decline of
initiator caspase activity was occurring due to the cleavage of cellular fragments by effector
caspases. The deregulation of intracellular proteins by cleavage into separate domains and the
destruction of cellular structures such as the nuclear lamina of cell is thus occurring past the 6hour mark of the experiment, which could be visualized with the executioner-targeting probe
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((DEVD)2R) (22).
The extension (IETD)2R experiments showed an average initial onset time of 1.8 ± 0.8
hours, and a duration of 120 ± 40 minutes, consistent with the preliminary 6-hour trials. Initiator
caspase activity was not affected by the extension of the time course and a full decrease in
overall activity was present (Figure 16) (Table 2).
Extended (9 Hour) Temporal Dynamics of Caspase Activation: Mean Onset Time and
Duration
Fluorogenic
Caspase
Probe

Median
Onset Time
of Caspase
Activity

Mean Onset
Time of
Caspase
Activity

Standard
Deviation of
Means

Median
Duration of
Caspase
Activity

Mean
Duration of
Caspase
Activity

Standard
Deviations
of Means

D2R

2.3 hours

2.4 hours

0.6 hours

360 minutes

340 minutes

60 minutes

1.6 hours

1.8 hours

0.8 hours

120 minutes

120 minutes

40 minutes

5.3 hours

5.2 hours

1 hours

120 minutes

130 minutes

60 minutes

(n=64)

(IETD)2R
Caspase-8
(n=83)

(DEVD)2R
Caspase-3
(n=105)

Table 2: The mean onset times and durations for the caspase activities determined from each of
the fluorogenic caspase probes used in the 9-hour time course (D2R, (IETD)2R and (DEVD)2R).
The fluorescence of ~100 fluorescent cells were traced using each probe. The onset times and
durations were determined for each cell individually. The mean was then taken for each data set
(onset time, duration).
The extension D2R trials portrayed an overall summation of the caspase activity
occurring within the cell. The extension trial showed that the initial caspase activation, resultant
of the initiator caspase activation as previously shown in the preliminary studies, began at 3.2 ± 1
hours. This was verified with the onset time determination using the (IETD)2R for the initiator
caspase activation of 1.8 ± 0.8 hours. The duration obtained for the extension of the initiator
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caspase activity was approximately equivalent to the duration in the preliminary studies, 120 ±
40 minutes. This signified that procaspase-8 autoactivation had ceased following the cleavage of
the effector procaspases and returned to the baseline inactive state as the executioner caspases
cleaved and destroyed the cell (23).
The extension (DEVD)2R experiments resulted in an average onset time of 5.2 ± 1 hours,
and a duration of 130 ± 60 minutes. Unlike the 6-hour time course, the extended trials allowed
for visualization of the decrease and subsequent cessation of executioner apoptotic activity in the
lymphocyte (Figure 17).
The delayed onset time of the executioner caspase was further reiterated with an average
initial activation of 5.2 ± 1 hours. Therefore, as the initiator caspase activity was declining, the
executioner caspase activity was inversely increasing. As more executioner caspases become
activated, a negative feedback is initiated to reduce the procaspse-8 cleavage and activation,
leading to the cessation of initiator caspase activity (22). The general caspase activity showed a
gradual decline and final termination on average of 7.3 hours, signifying the termination of
executioner activity. This was verified in the (DEVD)2R probe extension trials with a general
cessation of executioner activity at 7 hours: a duration of 130 ± 60 minutes from the onset time
of 5.2 ± 1 hours (Figure 16). The extension trials allowed for a clear termination to be
determined of executioner activity (Table 2).
The goal of this research was to understand the specific temporal dynamics of caspase
activity during the extrinsic process of apoptosis. Caspases, being the key effector molecules in
apoptosis, are potential targets for pharmacological modulation of cell death (27). Manipulation
of the timing of specific caspase activation is an important trait of apoptotic regulatory drug
therapies. Currently, therapeutic efforts are designed to regulate general caspase activity using
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non-specific caspase inhibitors to prevent their activation, which leads to diseases such as
Alzheimer’s and Parkinson’s. However, this will generally lead to the eventual triggering of a
caspase-independent form of cell death and is inefficient in isolating particular caspase activity
(31). If the individual activities of particular caspases were to be controlled, apoptosis could be
more greatly regulated which could be utilized in the creation of drug therapies designed to
target and kill tumor cells (29). The temporal dynamics of the caspase activation within the cell
is therefore an important construct in the design of the therapy, a design approach which had not
yet been investigated (28). With the extension experiments, a clear picture was obtained of the
specific timing of the caspases involved in the inducible pathway of apoptosis (Figure 17, Table
2). As caspase activation occurs through two major groups of caspases, the initiator caspases and
the executioner caspases, and the actions of caspase-8 represent that of the initiator caspases
while the activities of caspase-3 represent the executioner caspases, the exact timing within the
pathway was determined. While the intrinsically activated pathway of apoptosis experiences the
same effectuation stage as the extrinsic pathway, the pathway of induction differs as well as the
primary caspase to become activated. Chromatin degradation, leading to activation of the
intrinsic pathway, can be induced by administration of a hydrogen peroxide solution to induce
free radicals, oxidizing the DNA (32). However, the initiation process differs, including the
activation of the primary initiator caspase, caspase-9. Caspase-9 will cleave procaspase-3 in the
same manner as caspase-8. This difference is an area of interest in cancer research, as mutations
in most cancer cells lines creates resistance to the capsase-9 pathway (36).
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4. CONCLUSION
The goal of this work was to determine the temporal dynamics of the caspase activity in
Jurkat- T lymphocytes through initiation of apoptosis extrinsically. The timing of the caspase
activity was determined using fluorescence microscopy monitoring fluorogenic caspase probes
following the induction of apoptosis in the lymphocytes through anti- CD95 affinity binding. The
fluorogenic probe, a rhodamine 110 bis-substituted tetrapeptide molecule, is cleaved by
particular caspases within the cell, leading to the accumulation of R110 within the cellular
membrane. A preliminary time course of 6 hours did not allow for the full visualization of the
temporal activity of the executioner caspases. Therefore, with many modifications,
experimentation was able to be extended to a 9-hour time course. Application of the D2R probe
to the lymphocytes resulted in an average onset time of 2.39 ± 0.63 and a duration of 360 ± 63.7
minutes. Initiator caspases showed apoptotic activation 1.78 ± 0.75 hours post-ligand binding
and maintained activation for a duration of 120 ± 41.3 minutes. Executioner caspase activation
began 5.15 ± 0.95 hours post-binding and lasted 125 ± 56.1 minutes, with the termination of
effector caspase activity signifying the death of the cell (Figure 16).
Future studies will be conducted to determine the temporal dynamics of the intrinsically
activated caspase activation using the TCR antibody as a cellular capture method and hydrogen
peroxide inducer of intrinsic cellular damage. The TCR antibody binds the TCRα receptor on the
Jurkat lymphocyte surface, adhering the cell to the channel without spontaneously inducing the
apoptotic pathway (42).
Manipulation of the timing of caspase activation is an important concept in the design of
drug therapies to regulate apoptosis. In understanding when a caspase is activated (onset time)
and for how long it is activated (duration), targeted caspase therapies could be introduced in
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future research projects with ultimate oncologic applications. Inhibition of initiator caspase
activity could prevent apoptosis from occurring, while induction of caspase activation could
induce apoptotic in metastatic cancer cells. Controlled and isolated activation of specific
caspases could be important in future drug designs.
The temporal dynamics approach in this research additionally has several advantages.
The extension design of the microfluidic devices could assist in the design of the reusability of
these devices, which would ultimately increase the extremely low success rate of these
microfluidic procedures. This procedure could be conducted to examine the effect of membranepermeable caspase inhibitors and their resultant caspase activation, as well as the rate of the
caspase cleavage could be examined using this procedure. Finally, the microfluidic affinity
coating process could be applied to study the induction of other biological processes through
ligand binding.
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